000309608 001__ 309608
000309608 005__ 20260202155916.0
000309608 0247_ $$2doi$$a10.1007/s00066-026-02504-5
000309608 0247_ $$2pmid$$apmid:41615458
000309608 0247_ $$2ISSN$$a0179-7158
000309608 0247_ $$2ISSN$$a1439-099X
000309608 037__ $$aDKFZ-2026-00258
000309608 041__ $$aEnglish
000309608 082__ $$a610
000309608 1001_ $$00000-0002-0138-9930$$aGaasch, Aurélie$$b0
000309608 245__ $$aStereotactic heart ablative radiotherapy (SHARP): a prospective multicentric phase II trial.
000309608 260__ $$aHeidelberg$$bSpringer Medizin$$c2026
000309608 3367_ $$2DRIVER$$aarticle
000309608 3367_ $$2DataCite$$aOutput Types/Journal article
000309608 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770044309_1634725
000309608 3367_ $$2BibTeX$$aARTICLE
000309608 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000309608 3367_ $$00$$2EndNote$$aJournal Article
000309608 500__ $$a#DKTKZFB9# / epub
000309608 520__ $$aCardiac tumors are exceedingly rare with metastatic involvement representing the most frequent form of malignancy within the heart. In patients presenting with inoperable primary or recurrent malignant cardiac sarcomas or cardiac/epicardial/pericardial metastases, stereotactic body radiotherapy (SBRT) serves as an alternative local treatment to surgery or may, in some cases, constitute the sole viable local treatment modality. To date, there are only case reports or small retrospective studies assessing SBRT dose and toxicity for cardiac SBRT. The goal of this prospective multicentric observational study is to systematically evaluate the feasibility, toxicity and outcome of magnetic resonance-guided stereotactic body radiation therapy (MRgSBRT) in the management of primary and secondary cardiac malignancies.The treatment is performed using MR-guided SBRT in five fractions on non-consecutive days (6-8 Gy per fraction prescribed to the 80% isodose). Four study centers participate in this prospective phase II trial (Heidelberg, Munich, Rome, Zurich). Eligible patients who consent to participate in the study will undergo treatment as indicated and approved by an interdisciplinary tumor board. Primary objective is to assess the feasibility and safety of online adaptive MRgSBRT; secondary endpoints are local control and survival outcome, acute and late toxicity, patient-reported outcome as well as technical feasibility of treatment.The findings from this study may serve as a foundation for the future integration of cardiac SBRT into clinical practice guidelines for the management of cardiac malignancies.
000309608 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000309608 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000309608 650_7 $$2Other$$aCardiac
000309608 650_7 $$2Other$$aMR-guidance
000309608 650_7 $$2Other$$aMRgSBRT
000309608 650_7 $$2Other$$aOnline adaptive
000309608 650_7 $$2Other$$aSBRT
000309608 7001_ $$0P:(DE-HGF)0$$aMarschner, Sebastian N$$b1
000309608 7001_ $$aHoegen-Saßmannshausen, Philipp$$b2
000309608 7001_ $$aSandrini, Elisabetta$$b3
000309608 7001_ $$aHörner-Rieber, Juliane$$b4
000309608 7001_ $$aAndratschke, Nicolaus$$b5
000309608 7001_ $$aBalermpas, Panagiotis$$b6
000309608 7001_ $$aBoldrini, Luca$$b7
000309608 7001_ $$aRomano, Angela$$b8
000309608 7001_ $$aReiner, Michael$$b9
000309608 7001_ $$aNiyazi, Maximilian$$b10
000309608 7001_ $$aLindner, Lars$$b11
000309608 7001_ $$aWeckbach, Ludwig$$b12
000309608 7001_ $$aFink, Nicola$$b13
000309608 7001_ $$aHagl, Christian$$b14
000309608 7001_ $$0P:(DE-HGF)0$$aBelka, Claus$$b15
000309608 7001_ $$aCorradini, Stefanie$$b16
000309608 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-026-02504-5$$pnn$$tStrahlentherapie und Onkologie$$vnn$$x0179-7158$$y2026
000309608 909CO $$ooai:inrepo02.dkfz.de:309608$$pVDB
000309608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000309608 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000309608 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000309608 9141_ $$y2026
000309608 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-06$$wger
000309608 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-11-06$$wger
000309608 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2022$$d2025-11-06
000309608 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-06
000309608 9201_ $$0I:(DE-He78)MU01-20160331$$kMU01$$lDKTK Koordinierungsstelle München$$x0
000309608 980__ $$ajournal
000309608 980__ $$aVDB
000309608 980__ $$aI:(DE-He78)MU01-20160331
000309608 980__ $$aUNRESTRICTED